Jared Weiss, MD, discusses outcomes with first-line Versamune HPV plus pembrolizumab in HPV16–positive recurrent or metastatic HNSCC.
Novel Approaches in Treating HPV-Positive HNSCC
First-Line Versamune HPV Vaccine Bolsters Responses With SOC Pembrolizumab in HPV16+ Recurrent HNSCC
Jared Weiss, MD, discusses survival benefits seen with the therapeutic cancer vaccine Versamune HPV plus first-line pembrolizumab in HPV16-positive HNSCC.
Katharine A. Price, MD, discusses the potential role for injectable HPV-targeted immunotherapy vaccines in HPV16-positive head and neck squamous cell carcinoma.
Katharine A. Price, MD, discusses the use of HPV-targeted immunotherapy vaccines in patients with HPV16-positive head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5